A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study

INTRODUCTION: Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that might be a new therapeutic approach for managing anemia in patients with chronic kidney disease (CKD). We evaluated the efficacy (noninferiority to darbepoetin alfa [DA]) and safety of enarodust...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Kidney Int Rep
Glavni autori: Akizawa, Tadao, Nangaku, Masaomi, Yamaguchi, Takuhiro, Koretomo, Ryosuke, Maeda, Kazuo, Miyazawa, Yuya, Hirakata, Hideki
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2021
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258589/
https://ncbi.nlm.nih.gov/pubmed/34307978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.037
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items